

O/o. CS & GM (Legal)
Corporate Office
Bharat Sanchar Bhawan
2nd Floor, Ph/Fax: 011-2335 3395, 2335
3389



भारत संचार निगम लिमिटेड
(भारत सरकार का उपक्रम)
BHARAT SANCHAR NIGAM LIMITED
(A Govt. of India Enterprise)

Dated: 14th February, 2024

To

The Manager
Corporate Relationship Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

BSE Scrip Code- 960039 & 974458

Sub: Publishing unaudited Financial Results for the financial year ended on 31st December, 2023 in Newspaper under Regulation 52(8) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir,

Pursuant to the Regulation 52(8) of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, the unaudited financial results for quarter ended 31st December, 2023 published on 14th February, 2024 (Wednesday) in one English National Daily Newspaper i.e. Financial Express. Please find attached the copies of said publications along with the Board meeting the notice published on 09.02.2024.

We request you to kindly take the same on record.

Thanking You

Yours faithfully
For BHARAT SANCHAR NIGAM LIMITED


(J.P. CHOWDHARY)
Company Secretary & GM (L)

FINANCIAL EXPRESS

This advertisement is for information purposes only and does not constitute an offer or a recommendation to purchase, to hold or sell securities. This is not an announcement for the offer of offer.

GENPHARMASEC LIMITED

Our Company was originally incorporated as 'Gen-Pharmaceuticals' a private limited company with a certificate of incorporation dated 10th November, 1992, issued by the Registrar of Companies, District: Bhubaneswar.

PROMOTERS OF OUR COMPANY: MR. RAJESH SADHAWAN AND MRS. SURESH SADHAWAN

ATTENTION INVESTORS - CORRIGENDUM CUM ADDENDUM TO LETTER OF OFFER DATED JANUARY 09, 2024 AND CORRIGENDUM CUM ADDENDUM DATED JANUARY 20, 2024

NOTICE TO THE READER (NOTICE) - CORRIGENDUM CUM ADDENDUM TO LETTER OF OFFER DATED JANUARY 09, 2024 AND CORRIGENDUM CUM ADDENDUM DATED JANUARY 20, 2024

RIGHTS ISSUE PERIOD EXTENDED

ISSUE CLOSING DATE (OLD) - FRIDAY, 09th FEBRUARY, 2024

ISSUE CLOSING DATE (NEW) - TUESDAY, 13th FEBRUARY, 2024

Investors are informed that the date of closure of the rights issue, which opened on Tuesday, January 23, 2024 and scheduled to close on Friday, February 09, 2024 has now been extended from Friday, February 09, 2024 to Tuesday, February 13, 2024.

Accordingly, the last date of submission of the duly filled in Application Form on application is Tuesday, February 13, 2024. Equity Shareholders of the Company who are entitled to apply for the rights issue as mentioned above, are requested to take note of this extension of the issue closing date.

Investors may please note the letter of offer, amended letter of offer, common application form, corrigendum cum addendum to letter of offer dated January 20, 2024 shall be read in conjunction with this corrigendum cum addendum.

For Genpharmasec Limited on behalf of the Board of Directors

Ms. Heta Deepak Shah Company Secretary and Compliance Officer

Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has had a Letter of Offer dated January 09, 2024 with the Securities and Exchange Board of India and SEBI. The Letter of Offer is available on the website of SEBI at www.sebi.gov.in.

MIRC ELECTRONICS LIMITED

Regd. Office: One, House No. 01, MIRC, Mahatma Ghandi Road, Andheri East, Mumbai - 400033. CIN No.: L2820BH1992PLC232914

Extract of Statement of Unaudited Financial Results for the Quarter and Nine months ended 31st December, 2023. Table with columns for Particulars, Quarter ended (31-12-2023, 30-09-2023, 31-12-2022, 30-09-2022), Nine months ended (31-12-2023, 31-03-2023, 31-12-2022, 31-03-2022), and Year ended (31-12-2023, 31-03-2023, 31-12-2022, 31-03-2022).

Notes: 1. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

2. The above results are reviewed by the Audit Committee, have been taken on record by the Board of Directors on 06th February, 2024.

For MIRC ELECTRONICS LIMITED, C. L. Mischand, Chairman & Managing Director.

Bharat Sanchar Nigam Limited

(A Government of India Enterprise) CIN No.: 174999D12000(G1107319)

Regd. & Corporate Office: Bharat Sanchar Bhawan, H. C. Mathur Lane, Jangpoh, New Delhi-110001

NOTICE: Pursuant to Regulation 62(2)(c) read with regulation 50(1) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, the 13th day of February, 2024 at the registered office of the Company situated at Bharat Sanchar Bhawan, H.C.M. Lane, Jangpoh, New Delhi-110001, inter-alia to consider, approve and take on record, the financial results of the company for the quarter ended 31 December, 2023.

The details of the said meeting are also available on the website of the Company www.bsnl.in and on the website of the stock exchange www.bseindia.com.

For and on behalf of BHARAT SANCHAR NIGAM LIMITED, Sd/-, J.P. Choudhary, Company Secretary & GM (L).

Place: New Delhi Date: 6 February, 2024

KNR CONSTRUCTIONS LIMITED

Regd. Office: KNR House, 3rd & 4th Floor, Plot No. 114, Phase-I, Kowar, H.S. Hyderabad - 500033. Ph: 050-40287510 / 51-82. Fax: 040-40287600; website: knrindia.com. E-mail: investors@knrindia.com CIN: L74201G1999PLC130109

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

Table with columns for Particulars, Standalone (Quarter ended, Nine months ended, Year ended), and Consolidated (Quarter ended, Nine months ended, Year ended).

Notes: 1. The above Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on February 08, 2024.

2. The figures for the previous year/period have been retroactively classified to conform to the figures of the current period.

3. The above is an extract of the detailed format of Quarterly/ Nine months ended Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

4. The full format of the Quarterly and Nine months ended Financial Results is available on the website of the Stock Exchange viz. www.bseindia.com and National Stock Exchange of India Limited (www.nseindia.com) and on the Company's website www.knrindia.com.

AARTI INDUSTRIES LIMITED

Regd. Off: Plot Nos. 801, 801/23, Phase - III, G.I.D.C. Estate, Vapi-396195, Dist. Valsad, Gujarat. Head. Off: T/1, Udoy Kshetra, 2nd Floor, Mulund-Goregaon Link Road, Mulund (W), Mumbai-400 080

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

Table with columns for Particulars, Standalone (Quarter ended, Nine months ended, Year ended), and Consolidated (Quarter ended, Nine months ended, Year ended).

Notes: 1. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

2. The full format of the Quarterly Financial Results are available on the website of the Stock Exchanges viz. www.bseindia.com and www.nseindia.com and website of the Company i.e. www.aarti-industries.com.

For AARTI INDUSTRIES LIMITED, RAJENDRA V. GOGRI, CHAIRMAN AND MANAGING DIRECTOR.

AARTI PHARMALABS LIMITED

Registered Office: Plot No. 22/C1/1 & 22/C2, 1st Phase, GIDC Vapi-396195, Valsad, Gujarat. Corporate Office: 204, Udoy Kshetra, 2nd Floor, Mulund Goregaon Link Road, Mulund, West, Mumbai-400080, Maharashtra

Extract of Audited Financial Results for the Quarter and Nine Months ended December 31, 2023

Table with columns for Particulars, Standalone (Quarter ended, Nine months ended, Year ended), and Consolidated (Quarter ended, Nine months ended, Year ended).

Notes: 1. The above is an extract of the detailed format of Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

2. The full format of the Audited Financial Results are available on the website of the Stock Exchange viz. www.bseindia.com and www.nseindia.com and website of the Company i.e. www.aarti-pharmalabs.com.

3. The Financial Results have been prepared in accordance with Indian Accounting Standards (IndAS) prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended.

4. The Company has identified only one segment i.e. Pharmaceuticals as reporting segment.

5. The Board of Directors at its meeting held on 7th February 2024 have declared an Interim Dividend of Rs.2/- (40%) per equity share of Rs.5 each.

For AARTI PHARMALABS LIMITED, Sd/-, Hetal Gogri, Managing Director.

Mrs. Bectors Food Specialties Limited

Regd. Office: Thelod Road, Phillaur, Jalandhar-144410. Corporate (Company Number) (CIN): L78999PB1995PLC032417; PAH: AAQBMC9496K

Extract of Un-audited Consolidated Financial Results for the Quarter & Nine months ended 31st December, 2023 (Rs. in million except per share data)

Table with columns for Particulars, Quarter ended (31-12-2023, 30-09-2023, 31-12-2022, 30-09-2022), Nine months ended (31-12-2023, 31-03-2023, 31-12-2022, 31-03-2022), and Year ended (31-03-2023, 31-03-2022).

Extract of Un-audited Standalone Financial Results for the Quarter & Nine months ended 31st December, 2023 (Rs. in million except per share data)

Table with columns for Particulars, Quarter ended (31-12-2023, 30-09-2023, 31-12-2022, 30-09-2022), Nine months ended (31-12-2023, 31-03-2023, 31-12-2022, 31-03-2022), and Year ended (31-03-2023, 31-03-2022).

Notes: 1. The above standalone and consolidated unaudited financial results for the quarter and nine months ended 31st December, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors on 08th February, 2024.

2. The review report of the Statutory Auditor is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on unaudited financial results, visit financial performance section of our website www.bectorsfoods.com and financial results at appropriate section in www.bseindia.com and www.nseindia.com.

3. The Group is engaged in the single reporting segment 'Food products'.

4. The above is an extract of the detailed format of unaudited financial results for the quarter and nine months ended 31st December, 2023 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015. The full format of the unaudited financial results are available on the Stock Exchange websites www.bseindia.com and www.nseindia.com on the Company's website www.bectorsfoods.com.

For and on behalf of Board of Directors of Mrs. Bectors Food Specialties Limited, Sd/-, Anoop Bector, Managing Director.

Place: Phillaur Date: 08.02.2024